4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(2-aminocyclohexylamino)pyrimidine-5-carboxamide,
P505-15,
PRT062607,
PRT062607,
PRT-062607,
1370261-96-3,
UNII-K9C42672RH,
CHEMBL2177736,
K9C42672RH,
P505-15,
2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-5-pyrimidinecarboxamide,
2-{[(1r,2s)-2-Aminocyclohexyl]amino}-4-{[3-(2h-1,2,3-Triazol-2-Yl)phenyl]amino}pyrimidine-5-Carboxamide,
4-(3-(2H-1,2,3-Triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide,
TXGKRVFSSHPBAJ-JKSUJKDBSA-N,
BIIB057,
SCHEMBL899872,
BIIB-057,
GTPL8070,
5-Pyrimidinecarboxamide, 2-(((1R,2S)-2-aminocyclohexyl)amino)-4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-,
EX-A1592,
KS-000007GC,
BDBM50400047,
ZINC95572830,
AKOS025290289,
CS-3535,
PRT 062607,
NCGC00351606-09,
AK172489,
HY-15322,
P 505-15,
BRD-K53734668-003-04-6,
P505-15, PRT062607,PRT-2607, BIIB-057,
2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide,
4-((3-(2H-1,2,3-Triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide,
D0R9IU,
PRT-2607,
P-14276,
P-505-15,
Syk tyrosine kinase inhibitors (oral, cancers/inflammatory diseases/thrombosis), Portola,
1370261-97-4,
3YT,